Equity Profile

AMRX

Amneal Pharmaceuticals, Inc.

Health CarePharmaceuticals$6.0B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Amneal Pharmaceuticals, Inc. is a healthcare company that develops and manufactures generic and specialty pharmaceuticals....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.

$0.24

Revenue

Total revenue reflects the company's sales performance and growth potential, impacting overall market perception.

$811M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMRX Q2-2026 Earnings Preview

Context

Company Snapshot

Amneal Pharmaceuticals, Inc. is a healthcare company that develops and manufactures generic and specialty pharmaceuticals. With a market cap of $6 billion, it plays a significant role in the pharmaceutical industry, focusing on providing affordable medications to improve patient access and health outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+34.60%

Avg Stock Reaction

-0.24%

Last Quarter Recap

In Q1-2026, Amneal reported an EPS of $0.27, surpassing estimates by 8%. However, the stock experienced a slight decline of 1.54% the following day.

Management Promises & Guidance

Continue focusing on expanding the generic product portfolio.
Enhance operational efficiencies to improve margins.
Invest in research and development for specialty pharmaceuticals.

Expectations

Wall Street Expectations

Analysts expect Amneal to report solid earnings, with a consensus EPS of $0.24 and revenue of $811 million. The market is looking for continued growth in its generic and specialty drug segments.

Bull Case

If Amneal beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products, potentially driving the stock higher.

Bear Case

Conversely, if the company misses earnings expectations or provides weak guidance, it could raise concerns about its competitive position and growth prospects.

Key Metrics to Watch

EPS

$0.24

Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.

Revenue

$811M

Total revenue reflects the company's sales performance and growth potential, impacting overall market perception.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amneal achieve an EPS of $0.24 or higher?

This figure is critical as it reflects the company's profitability and could influence investor confidence.

What guidance will management provide for revenue growth?

Clear guidance on revenue expectations will be crucial for assessing the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Amneal's ability to leverage its recent product launches, which could drive higher-than-expected revenue growth.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with an 88% success rate over the last eight quarters.

Options pricing suggests a significant move, indicating that the market is anticipating potential volatility that could favor a positive outcome.

Key Risk

If revenue growth exceeds $811 million, it could challenge the current bearish sentiment and lead to a reassessment of the stock's value.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether Amneal can maintain its growth momentum in a competitive market.

Bull Confirmed If

Achieving an EPS of $0.24 or higher with revenue exceeding $811 million would confirm strong operational performance.

Bear Confirmed If

An EPS below $0.22 or revenue below $792 million would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±22.47%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±22.5% while AMRX has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

36.1%

Calls (400)P/C Ratio: 1.16Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amneal beats expectations, history suggests the stock could see an average one-day move of around +2.73%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a downside reaction, with historical data suggesting an average one-day move of +3.46% when expectations are not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the performance of new product launches.
2Management's commentary on competitive pressures in the generic market.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future revenue growth and market expansion plans.
5Discussion on R&D investments and their expected impact on specialty pharmaceuticals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Amneal Pharmaceuticals, Inc. is a healthcare company that develops and manufactures generic and specialty pharmaceuticals....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.

$0.24

Revenue

Total revenue reflects the company's sales performance and growth potential, impacting overall market perception.

$811M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+34.60%

Avg Stock Reaction

-0.24%

Last Quarter Recap

In Q1-2026, Amneal reported an EPS of $0.27, surpassing estimates by 8%. However, the stock experienced a slight decline of 1.54% the following day.

Management Promises & Guidance

Continue focusing on expanding the generic product portfolio.
Enhance operational efficiencies to improve margins.
Invest in research and development for specialty pharmaceuticals.

Expectations

Wall Street Expectations

Analysts expect Amneal to report solid earnings, with a consensus EPS of $0.24 and revenue of $811 million. The market is looking for continued growth in its generic and specialty drug segments.

Bull Case

If Amneal beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products, potentially driving the stock higher.

Bear Case

Conversely, if the company misses earnings expectations or provides weak guidance, it could raise concerns about its competitive position and growth prospects.

Key Metrics to Watch

EPS

$0.24

Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.

Revenue

$811M

Total revenue reflects the company's sales performance and growth potential, impacting overall market perception.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amneal achieve an EPS of $0.24 or higher?

This figure is critical as it reflects the company's profitability and could influence investor confidence.

What guidance will management provide for revenue growth?

Clear guidance on revenue expectations will be crucial for assessing the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Amneal's ability to leverage its recent product launches, which could drive higher-than-expected revenue growth.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with an 88% success rate over the last eight quarters.

Options pricing suggests a significant move, indicating that the market is anticipating potential volatility that could favor a positive outcome.

Key Risk

If revenue growth exceeds $811 million, it could challenge the current bearish sentiment and lead to a reassessment of the stock's value.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether Amneal can maintain its growth momentum in a competitive market.

Bull Confirmed If

Achieving an EPS of $0.24 or higher with revenue exceeding $811 million would confirm strong operational performance.

Bear Confirmed If

An EPS below $0.22 or revenue below $792 million would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±22.47%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±22.5% while AMRX has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

36.1%

Calls (400)P/C Ratio: 1.16Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amneal beats expectations, history suggests the stock could see an average one-day move of around +2.73%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a downside reaction, with historical data suggesting an average one-day move of +3.46% when expectations are not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the performance of new product launches.
2Management's commentary on competitive pressures in the generic market.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future revenue growth and market expansion plans.
5Discussion on R&D investments and their expected impact on specialty pharmaceuticals.